-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

Benzinga·06/01/2026 11:00:32
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.